June 22-25 | San Diego

2026 Program

At BIO 2026, where science meets real-world impact, you can access more than 135 sessions across 18 focus areas with discussions from leading biotechnology companies, investors, service providers, government officials, regulators and patient advocates.

Accelerate your career growth by adding a Professional Development Course to your BIO 2026 registration. Learn more.

Loading
9:00 AM (PT)
1:00 PM (PT)
  1. Company Presentations
    Company Presentations will take place in Theaters on the Exhibition Floor. Watch here for the detailed schedule, to be released in May. Find Presenting Companies in the Partnering system by filtering ...
    Company Presentation Session
    Loading

     
  2. This opening session of the 2026 BIO AI Summit will provide the latest data from Benchling on AI adoption rates across the biotechnology industry including benchmarks by size of organization, by degre ...
    AI Summit Session
    • AI and Digital Health
    28ABCDE
1:45 PM (PT)
  1. This session brings together leaders from pharma, AI technology, life sciences platforms, CROs, and specialized biotech AI to cut through the noise and examine how artificial intelligence is deliverin ...
    AI Summit Session
    • AI and Digital Health
    28ABCDE
  2. This intensive seminar provides biotech leadership teams with a practical, investor-facing playbook for raising institutional private capital. Designed for companies across stages, from early-stage pl ...
    Breakout Session
    • Business Development and Investment
    5B
  3. Real world data (RWD) are increasingly relied upon to inform drug policy decisions at both the state and federal levels. For example, state Prescription Drug Affordability Boards (PDABs) are using all ...
    Breakout Session
    • Value, Patient Access and Reimbursement
    26AB
2:00 PM (PT)
  1. Storytelling Stage
    The BIO Storytelling Stage is a showcase of the heart of BIO's priorities—sharing the stories of the biotechnology industry that show who we are, who we serve, what we do, and why we do it. You'll hea ...
    Storytelling Stage Storytelling Stage (Booth #3035)
    Sponsored by:
    Upload Image
    Loading
    1. Storytelling Stage Session
    2. Storytelling Stage Session
    3. Storytelling Stage Session
      Jillian Arnold, mother to two children with ASMD (Acid Sphingomyelinase Deficiency) will discuss the impacts of this disease on her family and what treatments are available now and on the near horizon ...
      Storytelling Stage Session Storytelling Stage (Booth #3035)

     
3:00 PM (PT)
  1. The United States is making unprecedented investments to reshore biomanufacturing, strengthen supply chains, and enhance national security. As new facilities rise across the country, a critical questi ...
    Breakout Session
    • Biomanufacturing
    30DE
  2. In biotech, success often hinges on spotting opportunities before anyone else does. Some of the industry’s most impactful companies have been built with smart business development regardless of their ...
    Breakout Session
    • Business Development and Investment
    30ABC
  3. In today's competitive biotech landscape, global reach is no longer a luxury—it's a prerequisite for winning. Panelists will reveal how global strategy is the defining competitive differentiator in bi ...
    Breakout Session
    • Emerging Opportunities in Global Markets
    31AB
    Sponsored by:
    Upload Image
  4. HBO Max’s “The Last of Us" captivated audiences with its gripping portrayal of a post-apocalyptic world ravaged by a fungal infection. While fictional, the threat posed by fungal pathogens is real. Fu ...
    Breakout Session
    • Infectious Disease and Vaccines
    31C
  5. For the first time in history, a patient has survived more than eight months following a gene-edited pig organ transplant, marking a pivotal moment as xenotransplantation moves from experimental promi ...
    Breakout Session
    • Next Generation Biotherapeutics
    24BC
  6. Biomarker legislation is reshaping insurance and diagnostics policy across many US states, with more than 20 currently mandating coverage for biomarker testing under certain conditions. However, trans ...
    Breakout Session
    • Value, Patient Access and Reimbursement
    26AB
3:15 PM (PT)
  1. Europe offers a uniquely compelling platform for pharmaceutical growth. World class science, deep talent pools, and leading research infrastructures underpin continuous innovation across the value cha ...
    Breakout Session
    • Business Development and Investment
    5B
4:15 PM (PT)
  1. This session will explore how quantum computing is poised to redefine the frontiers of drug discovery by solving complex molecular and optimization problems that exceed the limits of classical computi ...
    AI Summit Session
    • AI and Digital Health
    28ABCDE
  2. Clinical trials for large-population diseases face persistent challenges and remain the most complex and resource-intensive steps in drug development. Patient recruitment often lags, administrative bo ...
    AI Summit Session
    • AI and Digital Health
    29AB
  3. This panel will provide a multidimensional view into the Business Development engine room of a leading global healthcare company and present how different groups across Novo Nordisk collaborate to exp ...
    Breakout Session
    • Business Development and Investment
    32AB
    Sponsored by:
    Upload Image
  4. This session will feature a Fireside Chat with the former CEOand CBO of Capstan Therapeutics, as they share firsthand experience leading Capstan through one of the marquee M&A deals of 2025, a $2B+ ac ...
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
    30DE
  5. The China-US relationship will have a huge role in shaping the future of global biotech. Yet, this relationship is increasingly defined by both interdependence and tension — with science, supply chain ...
    Breakout Session
    • Emerging Opportunities in Global Markets
    29C
  6. The recent changes to vaccine recommendations, decision-making processes, and legislative frameworks—as well as the reversal of several of these changes—could impact vaccine access and innovation. The ...
    Breakout Session
    • Infectious Disease and Vaccines
    31AB
    Sponsored by:
    Upload Image
  7. Cardiovascular disease (CVD) remains the world’s leading cause of death, yet policy prioritization and investment continue to lag behind its health and economic impact. This session will explore how g ...
    Breakout Session
    • Next Generation Biotherapeutics
    31AB
    Sponsored by:
    Upload Image
  8. As the biopharmaceutical industry strives to address areas of high unmet medical need, there is increasing reliance on novel endpoints to accelerate and support drug development. In rare diseases, tra ...
    Breakout Session
    • Science and Regulatory Innovation
    23BC
  9. There’s no question that drug development is a risky endeavor with scientific, clinical, and commercial risk. Patients and society value advances in science that help people get well, stay healthy, an ...
    Breakout Session
    • Value, Patient Access and Reimbursement
    26AB
9:00 AM (PT)
10:00 AM (PT)
  1. BioProcess International Theatre
    BioProcess International Theatre BioProcess Theatre
    Loading
    1. Whether emerging or mature, branded, specialty or generic, Life Sciences manufacturers that have enabled Integrated Planning and Gross-to-Net analytical capabilities are more successful in meeting the ...
      BioProcess Session BioProcess Theatre
    2. As biologics programs approach Phase III and BLA submission, manufacturing decisions become strategic inflection points. Commercial geography, inspection exposure, and infrastructure resilience now di ...
      BioProcess Session BioProcess Theatre
    3. BioProcess Session BioProcess Theatre
    4. CDMO Capacity and Client Partnership Panel • How do you ensure your capacity planning aligns with actual client requirements rather than assumptions? • How do you balance multiple clients competing fo ...
      BioProcess Session BioProcess Theatre
    5. BioProcess Session BioProcess Theatre
    6. BioProcess Session BioProcess Theatre
    7. BioProcess Session
    8. BioProcess Session

     
10:30 AM (PT)
  1. Company Presentations
    Company Presentations will take place in Theaters on the Exhibition Floor. Watch here for the detailed schedule, to be released in May. Find Presenting Companies in the Partnering system by filtering ...
    Company Presentation Session
  2. Join us for Regional Presentations.
    Global Innovation Hub
    Loading
    1. Choose Québec, a thriving environment for precision medicine Québec is a major hub for health biotech, fostering precision medicine innovation. Global leaders like Abbott, GSK, Medicago, Merck, Moderna, Novartis, and Sandoz operate here. The province offers affordable infrastructure, dedicated life sciences hubs, and low operating costs. Government support includes tax credits and investment funds. With 30,000 students in life sciences and 7,600 graduates yearly, Québec has a strong talent pool. Top universities excel in AI, bioinformatics, genomics, and immuno-oncology. The province also leads in biomarkers, diagnostics, gene therapy, and cell therapy. Cutting-edge research infrastructure strengthens its precision medicine ecosystem.
      Global Innovation Hub Session
    2. Seoul: Asia’s Strategic Bio & Clinical Innovation Hub Seoul is an emerging bio hub where clinical development, R&D, capital, and advanced manufacturing converge. The city hosts a dense ecosystem of over 1,200 biotech and life sciences companies, leading universities, and world-class hospitals, enabling strong collaboration and open innovation. With near-universal healthcare coverage, Seoul provides access to large-scale real-world data, supporting fast and efficient clinical research. Korea consistently ranks among the top countries globally in clinical trial activity, positioning Seoul as a leading clinical hub in Asia. Together, this integrated ecosystem makes Seoul a strategic gateway for biotech innovation and expansion across the Asia-Pacific region.
      Global Innovation Hub Session
    3. Sweden’s life science industry is a globally competitive and innovation-driven sector, spanning pharmaceuticals, biotechnology, medical technology, and digital health. Built on a strong foundation of academic excellence and public-private collaboration, the ecosystem connects leading universities, research institutes, healthcare providers, and companies of all sizes. Key hubs such as Stockholm-Uppsala, Gothenburg, and Medicon Valley foster entrepreneurship and attract international investment. With a focus on precision medicine, sustainability, and patient-centered care, Sweden continues to play a significant role in advancing global health.
      Global Innovation Hub Session
    4. Catalonia is a a Top European Hub in Scientific Excellence and R&D, ranking #1 in Horizon projects per capita and #4 in ERC grants, with the highest share of Highly Cited Papers. Its BioRegion hosts 1,650 companies, 94 research centres and 17 of the world’s top 20 pharma/medtech multinationals, and is Spain’s main pharmaceutical manufacturing hub with 79 plants. It is #7 worldwide and #4 in Europe in active clinical trials, participating in 92% of Spain’s studies, supported by hospitals excelling in advanced therapies and early‑phase research. In 2025, investment reached a record €517M, with 82% international VC, driven largely by biotech. Catalonia also offers exceptional talent, producing 26,000 STEM graduates annually, employing 18,500 researchers, and attracting 30+ new digital and health innovation hubs, including AstraZeneca’s €1.3B Global Hub in Barcelona, a major boost to the region’s innovation capacity.
      Global Innovation Hub Session
    5. France Biotech was founded in 1997 as an independent association, uniting the country’s leading innovative health companies and their expert partners. As a key facilitator of the health innovation ecosystem and a privileged point-of-contact for public authorities in France and Europe, France Biotech helps address the major challenges facing the HealthTech sector (including company financing, taxation, regulatory and market access issues, etc.). Its committees and working groups strive to identify viable solutions to create the necessary conditions for a competitive and attractive industry. Its objective is to support HealthTech startups and SMEs in becoming successful international companies capable of designing and developing innovative products and solutions rapidly and ultimately making them accessible to patients. France Biotech is the French equivalent of the US BIO (Biotechnology Innovation Organization). Lyonbiopôle is the health innovation cluster of the Auvergne-Rhône-Alpes region. It connects and supports industrial companies, SMEs, academic institutions, and healthcare stakeholders in the development of innovative solutions in biotech, medtech, and digital health. As a member of the national alliance of health clusters, Enosis Santé, Lyonbiopôle gives you access to some of the most dynamic health ecosystems and networks in France. Whether you work in oncology, neurology, or infectious diseases, or whether you are developing or manufacturing an ATMP, France offers high-level networks to help accelerate your innovation.
      Global Innovation Hub Session
    6. France Biotech was founded in 1997 as an independent association, uniting the country’s leading innovative health companies and their expert partners. As a key facilitator of the health innovation ecosystem and a privileged point-of-contact for public authorities in France and Europe, France Biotech helps address the major challenges facing the HealthTech sector (including company financing, taxation, regulatory and market access issues, etc.). Its committees and working groups strive to identify viable solutions to create the necessary conditions for a competitive and attractive industry. Its objective is to support HealthTech startups and SMEs in becoming successful international companies capable of designing and developing innovative products and solutions rapidly and ultimately making them accessible to patients. France Biotech is the French equivalent of the US BIO (Biotechnology Innovation Organization).
      Global Innovation Hub Session
    7. Queensland, Australia is a rapidly growing biomedical innovation hub and a strategic gateway to the Asia-Pacific region. Anchored by world-class research institutes, hospitals, and industry, the state delivers end-to-end capability from discovery to global impact: home to breakthroughs such as the Gardasil vaccine and innovations like The University of Queensland’s molecular clamp technology, now being advanced globally by companies such as ViceBio/Sanofi. Queensland features dedicated innovation hubs, advanced biomanufacturing infrastructure, and a globally competitive clinical trials environment. With strong collaboration, cost advantages, and access to diverse patient populations, it offers an ideal platform for developing and scaling biomedical innovations for global markets.
      Global Innovation Hub Session
    8. JBA is the largest and oldest biotechnology association in Japan, aiming to promote international open innovation and collaboration between Japan and the rest of the world.
      Global Innovation Hub Session
      • Other
    9. An brief overview of support that the Japanese government offers to foreign companies looking to expand into Japan.
      Global Innovation Hub Session
    10. Taiwan has targeted precision health, advanced manufacture, and digital health as its key elements for biomedical industry development. Besides a well-established infrastructure and various unique biomedical clusters, the government has launched regulations to promote new sectors of biomedical industry, such as cell therapies, digital health, and CDMO. This presentation will update the progress for the biomedical ecosystem in Taiwan, including incentives for advancing together with Taiwanese partners.
      Global Innovation Hub Session
    11. The Department for Business and Trade (DBT) is the UK Government department responsible for growing the economy through trade, investment, and business growth. DBT champions the UK as a leading global destination for life sciences innovation and investment. Working across government, industry, and the NHS, the department supports international companies looking to establish or expand operations in the UK, across R&D, clinical trials, manufacturing, and commercialization.
      Global Innovation Hub Session
      • Non-Profit/Patient Advocacy Group
    12. We will present an update from the Global Innovation Hub Switzerland including general trends in financing, partnering and international collaborations, and opportunities to liaise with the > 1500 Swiss biotech companies.
      Global Innovation Hub Session
    13. Invest in Italy: discover a vibrant Pharma & Biotech industry
      Global Innovation Hub Session
    14. The Netherlands offers a highly collaborative and innovation-driven Life Sciences & Health (LSH) ecosystem, positioning itself as a leading gateway to Europe’s Life Sciences & Health Metropolis. This presentation provides an overview of the Dutch LSH landscape, highlighting strong public-private partnerships, world-class research infrastructure, and a supportive regulatory and funding environment. With a dense network of innovative companies, top-tier knowledge institutions, and strategic government support, the Netherlands enables rapid translation from research to market. Attendees will gain insights into key strengths such as integrated health data systems, clinical trial readiness, and a focus on value-based healthcare. The session also explores opportunities for international collaboration, investment, and market entry, showcasing why the Netherlands is an attractive partner for global LSH stakeholders.
      Global Innovation Hub Session
    15. The Government of the State of Mexico will present its value proposition as a strategic hub for life sciences, highlighting its capabilities in pharmaceutical manufacturing, research, clinical development and investment attraction. As part of the MEXBIO Pavilion at BIO International Convention 2026, this presentation will showcase the State’s role in strengthening Mexico’s position within the global biotechnology ecosystem, aligned with national priorities such as Plan México. With a strong industrial base, skilled talent and proximity to one of the world’s largest healthcare markets, the State of Mexico offers opportunities for international collaboration across R&D, manufacturing and market access. The session aims to connect global partners with regional opportunities, fostering investment, innovation and cross-border partnerships in life sciences.
      Global Innovation Hub Session
    16. The CEO of the Andhra Pradesh Economic Development Board will present the state’s vision to emerge as a leading biomanufacturing hub in India. The session will highlight Andhra Pradesh’s rapidly evolving bioecosystem, with a focus on Visakhapatnam as a key growth centre supported by strong infrastructure, talent availability, and industry presence. The presentation will outline major upcoming initiatives, including the development of a Biotechnology Park and a state-of-the-art Quantum BioFoundry aimed at enabling next-generation bio-innovation and scale-up. It will also cover the state’s proactive policy framework designed to attract global investments, foster industry–academia collaboration, and support advanced biomanufacturing. Aligned with the Government of India’s BioE3 policy, Andhra Pradesh is positioning itself as a competitive destination for global life sciences companies seeking integrated ecosystems for research, development, and manufacturing.
      Global Innovation Hub Session
    17. The Department of Health – Abu Dhabi (DoH) is the regulator and strategic lead for Abu Dhabi's healthcare life-science (HLS) sector, and the stratgic lead of the HELM Cluster (an integrated platform spanning genomics, digital health, advanced therapies, clinical trials, and biomanufacturing). Abu Dhabi offers global partners a sovereign-backed environment combining the world's largest genomics program (900K+ genomes), nationally connected health data, accelerated regulatory pathways (8–15 day clinical trial approvals), strategic capital commitments to biotech infrastructure, and targeted incentive packages for R&D, manufacturing, and commercialization. Positioned as a neutral, competitive destination at the frontier of bioconvergence where genomics, AI, and clinical delivery converge at scale. Abu Dhabi is building the next global hub for healthcare life-science innovation and growth.
      Global Innovation Hub Session
      • Non-Profit/Patient Advocacy Group

     
11:00 AM (PT)
  1. Storytelling Stage
    The BIO Storytelling Stage is a showcase of the heart of BIO's priorities—sharing the stories of the biotechnology industry that show who we are, who we serve, what we do, and why we do it. You'll hea ...
    Storytelling Stage Storytelling Stage - Booth 3035
    Sponsored by:
    Upload Image
    Loading
    1. Storytelling Stage Session
    2. Storytelling Stage Session
    3. Storytelling Stage Session
    4. Storytelling Stage Session
    5. Storytelling Stage Session
    6. Storytelling Stage Session
    7. Storytelling Stage Session
      Storytelling Stage Session Storytelling Stage (Booth #3035)
    8. Storytelling Stage Session
    9. Storytelling Stage Session
      Storytelling Stage Session Storytelling Stage (Booth #3035)
    10. Storytelling Stage Session
    11. Storytelling Stage Session

     
  2. The next evolution of AI in biopharma is already here - systems designed not just to analyze data but to make decisions. These “agentic AI” models can set goals, adapt strategies, and generate hypothe ...
    Breakout Session
    • AI and Digital Health
    31AB
  3. As major patent expirations loom, pricing pressures intensify and R&D productivity comes under strain, large pharmaceutical companies are accelerating dealmaking to fill therapeutic and clinical-stage ...
    Breakout Session
    • Business Development and Investment
    30ABC
  4. Healthcare providers are often faced with the same set of challenges when diagnosing women with Alzheimer’s – debunking the stigma that has shaped the Alzheimer’s narrative for women and their familie ...
    Breakout Session
    • Patient Advocacy
    31C
  5. Kickstart your journey in biotechnology by exploring the industry’s vast landscape and discovering where your skills and interests can make an impact. Experts will provide an overview of biotech acros ...
    Breakout Session
    • Special Program
    29AB
  6. The life sciences industry is built on innovation and driven by purpose. As competing for talent and earning public trust become critical business drivers, leading life sciences companies are investin ...
    Breakout Session
    • Workforce, Health Equity, and Leadership
    26AB
12:15 PM (PT)
  1. Super Session
    The biopharma industry has reached a critical inflection point. While pioneering new scientific frontiers, the industry faces challenges from global budgetary pressures and, in the U.S., structural di ...
    Super Session 28ABCDE
    Sponsored by:
    Upload Image
1:45 PM (PT)
  1. AI is redefining what’s possible across industries, and nowhere is the opportunity greater than in life sciences. But unlocking its full power requires more than algorithms — it demands bold new ways ...
    Breakout Session
    • AI and Digital Health
    31AB
  2. Macroeconomic challenges that have hindered biotech IPO activity are subsiding and capital markets are expected to improve later in 2026, especially for early-stage biotech companies. Increased M&A ac ...
    Breakout Session
    • Business Development and Investment
    25ABC
  3. This data-driven session from BIO and its market intelligence partner, Norstella, will dive into the state of play for emerging biotech companies. From venture capital and public financing, deal-makin ...
    Breakout Session
    • Business Development and Investment
    29AB
  4. This session will explore how pharma/biotech companies achieve pipeline diversity through portfolio strategy, strategic collaborations, and scientific rigor. The conversation will examine the processe ...
    Breakout Session
    • Business Development and Investment
    30ABC
  5. Rare diseases collectively affect more than 300 million people worldwide, yet fewer than 5% have an approved treatment. As cell and gene therapies (CGTs) progress from scientific aspiration to commerc ...
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
    32AB
  6. Super Session
    Advances in biotechnology are rewriting medicine and redefining the patient experience. At the forefront of each scientific breakthrough are the patients who made it possible. This session celebrates ...
    Super Session
    • Patient Advocacy
    28ABCDE
  7. Nearly a year ago, the One Big Beautiful Bill became law and states immediately felt the implications of its sweeping health care provisions. This session will provide a cross-stakeholder view on how ...
    Breakout Session
    • Value, Patient Access and Reimbursement
    30DE
    Sponsored by:
    Upload Image
2:40 PM (PT)
  1. BioProcess International Theatre
    BioProcess International Theatre BioProcess Theatre
    Loading
    1. Affordability remains a key challenge for biologic medicines, particularly for mature products under increasing cost and access pressure. Beyond innovation at the molecule level, manufacturing efficie ...
      BioProcess Session
    2. What manufacturing innovations have delivered the most significant cost reductions while maintaining product quality in your biologics operations? How are you balancing the capital investment required ...
      BioProcess Session BioProcess Theatre

     
3:00 PM (PT)
  1. AI-enabled discovery and multimodal, human-centric datasets are reshaping how biopharma and digital health companies differentiate, partner, and scale. Rather than focusing on capital trends, this ses ...
    Breakout Session
    • AI and Digital Health
    31AB
  2. Novel manufacturing technologies can help rapidly scale manufacturing capabilities, increase supply chain resilience, bring manufacturing closer to the patient, and support greener manufacturing. On a ...
    Breakout Session
    • Biomanufacturing
    23BC
  3. Women’s health is now a dynamic arena for innovation, data science, and strategic capital deployment. This session brings together leading investors to discuss where smart capital is flowing and how s ...
    Breakout Session
    • Business Development and Investment
    25ABC
  4. As life sciences innovation becomes increasingly global, many emerging biotech ecosystems continue to face barriers to accessing the capital, infrastructure, and networks that define established hubs ...
    Breakout Session
    • Business Development and Investment
    30ABC
  5. Respiratory syncytial virus (RSV) is a leading cause of severe respiratory illness globally and a major driver of hospitalization in infants under one year. The introduction of RSV immunization for in ...
    Breakout Session
    • Infectious Disease and Vaccines
    31C
    Sponsored by:
    Upload Image
3:10 PM (PT)
  1. Super Session
    Superhuman Body: World of Medical Marvels, narrated by Matthew McConaughey, takes audiences inside the remarkable capabilities of the human body and the breakthroughs in science and bioengineering tha ...
    Super Session
    • Patient Advocacy
    28ABCDE
4:15 PM (PT)
  1. For years, therapeutic development for Alzheimer’s and other neurodegenerative diseases has focused on the pathologies within the brain such as, in the case of Alzheimer’s, amyloid plaques and tau tan ...
    Breakout Session
    • Brain Health
    24BC
  2. Super Session
  3. With federal agencies commitments being uncertain and wavering, many researchers as well as emerging drug and device developers are struggling to find funding or to continue projects. At the same time ...
    Breakout Session
    • Business Development and Investment
    30ABC
  4. Many Western biopharma leaders look back and wish they had engaged earlier with the China story. A similar inflection point is now unfolding in Korea, and the time to engage early is now. South Korea ...
    Breakout Session
    • Emerging Opportunities in Global Markets
    23BC
  5. The metabolic disease treatment landscape is transforming rapidly. While GLP-1 receptor agonists have demonstrated remarkable efficacy, addressing the full scope of metabolic dysfunction requires ther ...
    Breakout Session
    • Next Generation Biotherapeutics
    32AB
  6. The landmark ORPHAN Cures Act has catalyzed investment in rare disease research since its passage last year, bringing hope to millions of patients and their families. Early data demonstrates renewed p ...
    Breakout Session
    • Orphan and Rare Disease
    31C
    Sponsored by:
    Upload Image
  7. We are living in a golden age of biopharmaceutical innovation. Yet, too often, patients face barriers between them and the appropriate treatment they need across various cost-shifting programs. Payers ...
    Breakout Session
    • Patient Advocacy
    29C
  8. As we approach 50 years of biotechnology innovation, a generation of female leaders are reshaping the industry at some of the most influential companies in biopharma, including as CEOs of Vertex and A ...
    Breakout Session
    • Workforce, Health Equity, and Leadership
    26AB
9:00 AM (PT)
9:30 AM (PT)
  1. BioProcess International Theatre
    BioProcess International Theatre BioProcess Theatre
    Loading
    1. This presentation describes the progress of a stem-cell therapeutic & commercial development from phase 3 and lessons learned. Specific challenges existing within the stem cell therapeutics and regene ...
      BioProcess Session BioProcess Theatre
    2. BioProcess Session BioProcess Theatre

     
10:30 AM (PT)
  1. Company Presentations
    Company Presentations will take place in Theaters on the Exhibition Floor. Watch here for the detailed schedule, to be released in May. Find Presenting Companies in the Partnering system by filtering ...
    Company Presentation Session
11:00 AM (PT)
  1. BioProcess International Theatre
    BioProcess International Theatre BioProcess Theatre
    Loading

     
  2. Storytelling Stage
    The BIO Storytelling Stage is a showcase of the heart of BIO's priorities—sharing the stories of the biotechnology industry that show who we are, who we serve, what we do, and why we do it. You'll hea ...
    Storytelling Stage Storytelling Stage - Booth 3035
    Sponsored by:
    Upload Image
  3. Federated learning is a machine learning approach that trains models across decentralized datasets without pooling patient-level data into a central repository. For biotechnology executives, it can ac ...
    Breakout Session
    • AI and Digital Health
    30DE
    Sponsored by:
    Upload Image
  4. The 36th edition of EY’s Beyond Borders Biotechnology Report provides an in-depth look at the US and European biotech industry as the operating and regulatory ecosystem is undergoing dramatic changes. ...
    Breakout Session
    • Business Development and Investment
    25ABC
  5. As diagnostics and precision medicine continue to advance, companies developing novel diagnostic technologies, analytical tools, and data-enabled testing solutions are reshaping how disease is detecte ...
    Breakout Session
    • Diagnostics and Personalized Medicine
    26AB
  6. As the life sciences industry continues its expansion, the demand for highly skilled talent frequently outpaces local supply. Solving this bottleneck requires more than isolated efforts; it demands a ...
    Breakout Session
    • Special Program
    24BC
12:15 PM (PT)
  1. Super Session
    Explore how Saudi Arabia is building an integrated biotech ecosystem: agile regulation, targeted incentives, national genomics data assets, and enabling infrastructure to become a regional and global ...
    Super Session
    • Emerging Opportunities in Global Markets
    28ABCDE
    Sponsored by:
    Upload Image
1:40 PM (PT)
  1. BioProcess International Theatre
    BioProcess International Theatre BioProcess Theatre
    Loading
    1. Analytical technologies and methods play a pivotal role in quality attribute understanding and control which are essential to the rapidly evolving filed of biologics development and manufacturing. Thi ...
      BioProcess Session BioProcess Theatre
    2. This presentation explores practical applications of artificial intelligence across biopharmaceutical CMC, focusing on real-world use in GMP environments. It highlights AI-driven approaches to QMS, de ...
      BioProcess Session BioProcess Theatre
    3. As biopharmaceutical pipelines grow increasingly diverse — encompassing monoclonal antibodies, recombinant proteins, gene therapies, cell therapies, and other novel modalities — the pressure to stream ...
      BioProcess Session BioProcess Theatre

     
1:45 PM (PT)
  1. Although artificial intelligence (AI) has existed for decades, recent advances in computational power, data availability, and machine learning models have significantly accelerated its development and ...
    Breakout Session
    • AI and Digital Health
    30DE
  2. In recent years, a confluence of global economic, market, and policy shifts have led to the abandonment of more than 1,000 promising treatments in development for rare diseases - many of which deliver ...
    Breakout Session
    • Business Development and Investment
    25ABC
  3. The biotech ecosystem is navigating real headwinds — tighter capital, increasingly complex science, and an increasingly unforgiving path from discovery to clinic. But pressure also creates openings. T ...
    Breakout Session
    • Business Development and Investment
    29AB
    Sponsored by:
    Upload Image
  4. Both Secretary Kennedy and Commissioner Makary have signaled that there will be a new era of “radical transparency” at the Food and Drug Administration (FDA). Regulatory transparency is generally desi ...
    Breakout Session
    • Intellectual Property and Legal Landscape
    29C
  5. Longevity science has entered its execution era. What once sounded speculative now rests on clearer biology, richer human datasets, and maturing toolkits that are pushing longevity from buzzword to bu ...
    Breakout Session
    • Next Generation Biotherapeutics
    31C
3:00 PM (PT)
  1. Until recently, drug discovery has been limited by fundamental practical constraints such as the range of proteins that exist in nature or the availability of samples, time, and funding for experiment ...
    Breakout Session
    • AI and Digital Health
    31AB
  2. Biomanufacturing is at an inflection point. From the outside‑in, macro forces - significant near‑shoring investments over the next 3–5 years, costing pressures, and the need for regional, resilient su ...
    Breakout Session
    • Biomanufacturing
    32AB
  3. This panel discussion addresses a critical paradox in biotechnology investment - while female-founded biotech’s demonstrate superior returns, they receive less than 3% of venture funding. This session ...
    Breakout Session
    • Business Development and Investment
    30ABC
  4. Inherited Retinal Diseases (IRDs) were once considered untreatable, leaving patients and families facing the certainty of progressive vision loss. Today, advances in gene therapy are changing that rea ...
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
    26AB
  5. For decades, autoimmune disease therapy has been defined by one trade-off - suppressing the immune system to relieve symptoms. That paradigm is now breaking. The 2025 Nobel Prize in Physiology of Medi ...
    Breakout Session
    • Next Generation Biotherapeutics
    31C
  6. For 87 years, our industry had to operate under an uncomfortable truth: over 90% of cancer drugs that "cure" mice routinely fail patients in clinical trials. In 2022, the FDA Modernization Act 2.0 too ...
    Breakout Session
    • Oncology
    24BC
  7. The 340B program was initially intended to help safety net hospitals further serve vulnerable communities. However, the program has now ballooned into a massive profit generator for hospitals that oft ...
    Breakout Session
    • Patient Advocacy
    23BC
  8. Super Session
    This session will explore the latest developments at the European Medicines Agency (EMA) regarding review processes, technological trends, and policy innovations via a moderated discussion with Execut ...
    Super Session
    • Science and Regulatory Innovation
    28ABCDE
4:15 PM (PT)
  1. Europe's decades-long decline in pharmaceutical R&D and delay in patient access to medicines are the direct result of government policies designed to lower spending on innovative medicines, including ...
    Breakout Session
    • Business Development and Investment
    25ABC
  2. Super Session
    This session will shed light on the recent acquisition of Akero Therapeutics by Novo Nordisk. The two panelists played a key role in forging this deal and will share their perspective on the journey t ...
    Super Session
    • Business Development and Investment
    28ABCDE
    Sponsored by:
    Upload Image
  3. Back by popular demand, this session returns with fresh insights for 2026. Health and science executives will learn how to build and deliver an investor-ready story using LaVoieHealthScience’s LHS Fif ...
    Breakout Session
    • Business Development and Investment
    30ABC
  4. The FDA’s new guidance supporting non-animal testing methods is reshaping preclinical drug development, creating unprecedented opportunities for biotech innovation. This session brings together biotec ...
    Breakout Session
    • Next Generation Biotherapeutics
    29C
  5. Enacted in 1992, the Prescription Drug User Fee Act (PDUFA) establishes how regulated industry fees support the human drug review program at the Food and Drug Administration (FDA) and associated Agenc ...
    Breakout Session
    • Science and Regulatory Innovation
    29AB
9:00 AM (PT)
  1. In an increasingly selective capital environment, a handful of biotech CEOs have managed to defy the odds—closing $100 million-plus financing rounds that fueled major growth, platform expansion, and p ...
    Breakout Session
    • Business Development and Investment
    25ABC
  2. CAR-T cell therapy has fundamentally transformed outcomes for patients with certain hematologic malignancies and, increasingly, solid tumors — yet the vast majority of eligible patients never receive ...
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
    30ABC
  3. The biopharmaceutical industry faces persistent misinformation campaigns targeting patent practices, with myths about patent thickets, evergreening, and excessive patent filings driving misguided poli ...
    Breakout Session
    • Intellectual Property and Legal Landscape
    29C
  4. Over the past five decades, the Langer Lab has played a central role in shaping modern biotechnology—founding more than 40 companies and training over 1,000 scientists, many of whom are now professors ...
    Breakout Session
    • Next Generation Biotherapeutics
    30DE
10:00 AM (PT)
  1. Company Presentations
    Company Presentations will take place in Theaters on the Exhibition Floor. Watch here for the detailed schedule, to be released in May. Find Presenting Companies in the Partnering system by filtering ...
    Company Presentation Session
  2. Storytelling Stage
    The BIO Storytelling Stage is a showcase of the heart of BIO's priorities—sharing the stories of the biotechnology industry that show who we are, who we serve, what we do, and why we do it. You'll hea ...
    Storytelling Stage Storytelling Stage - Booth 3035
    Sponsored by:
    Upload Image
10:15 AM (PT)
  1. Cell and gene therapies have become invaluable modalities in the medicine toolkit. Following recent safety concerns with AAV vector technology, experts will look increasingly toward new vectors and de ...
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
    26AB
  2. Since the first drugs were selected for “negotiation,” the Inflation Reduction Act (IRA) has been the target of litigation. Two strains of litigation emerged, with one focusing on the constitutionalit ...
    Breakout Session
    • Intellectual Property and Legal Landscape
    30DE
  3. The path from academic discovery to patient impact has never been more complex. Federal funding shifts, market turbulence, and evolving expectations for commercialization are challenging traditional m ...
    Breakout Session
    • Translational Research
    29AB

white squarewhite

BIO DOUBLE HELIX SPONSORS

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

BIO HELIX SPONSORS

Loading